Maynard Um
-
-
-
-
-
-
-
Fate Therapeutics presents lupus trial data showing patient responses
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis
-
-
-
-
-
-
-
Fate Therapeutics (FATE) PT Lowered to $8 at Jefferies
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Fate Therapeutics (FATE)
-
-
-
-
-
-
-
Fate Therapeutics (FATE) PT Lowered to $5 at Stifel
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

